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Summary 
Fas antigen and two tumor necrosis factor receptors (TNFR), p55 and p75, are implicated in 
the triggering of cell death upon stimulation by natural ligands and specific monoclonal antibodies. 
However,  the relative efficiency of each receptor, the mechanisms that regulate their function 
and the signaling pathways they employ, remain to be elucidated. In this study, fusion proteins, 
composed of the extracellular domain of CD40 and the intracellular and transmembrane domains 
of Fas, TNFRp55 and TNFRp75, were stably expressed in a human melanoma cell line that 
is deficient in Fas and TNFR expression. Transfectants were stimulated by a soluble recombinant 
form of the CD40 ligand gp39, and the effect on cell viability determined. Engagement of all 
three fusion proteins by the gp39 ligand induced lethal signals, but the rate at which cell death 
occurred was distinct. Fas-derived signals were observed to have the most rapid effect, killing 
most cells within hours of stimulation, whereas TNFILp55- and TNFILp75-associated signals 
resulted in cell death within 2-3 d after engagement by ligand. It is interesting to note that 
optimal cell killing by all three fusion proteins was dependent on a critical, low to intermediate, 
cell surface expression level. High levels of fusion protein expression,  on the other hand, were 
associated with inhibition of cell death. Our results provide a model to study Fas and TNFR- 
mediated cell death and suggest a novel mechanism for the regulation of death signals triggered 
by members of the TNFR family. 
M 
echanisms that regulate cell death are essential for normal 
development and maintenance of homeostasis. Cell 
death can be developmentally controlled, by the expression 
of novel genes that induce the death signal at a specific stage 
of differentiation in response to defined physiologic stimuli 
(1). The most common morphologic expression of such pro- 
grammed cell death is apoptosis, characterized by cell shrinkage, 
zeiosis, or blebbing, of the plasma membrane, and nuclear 
collapse and fragmentation of the nuclear chromatin at in- 
teruucleosomal sites  due  to  activation of an  endogenous 
nuclease (1-5).  However, lethal cellular programs that lead 
to apoptosis may also be triggered by a variety of exogenous 
or environmental stimuli. Some of these are cell type specific, 
including glucocorticoid-dependent lymphocyte killing (6), 
antigen receptor-associated thymocyte death (7, 8) and TGF- 
B-induced hepatocyte death, whereas others are effective on 
a broad range of cells, including target cell lysis by cytotoxic 
T cells (9), radiation-induced DNA damage (10, 11) and en- 
gagement of specific cell surface receptors by natural ligands 
or antibodies (3, 4). Recently, three structurally related cell 
surface receptors implicated in transduction of death signals 
in a broad range of cell types have been identified and charac- 
terized. They include the Fas antigen (12, 13), and two dis- 
tinct TNFR chains, p55 (14-16) and p75 (17, 18). All three 
receptors belong to a family of cell surface glycoproteins that 
includes nerve growth factor receptor (19), the T cell antigen 
CD27 (20), the B cell receptor CD40 (21), and the T cell-as- 
sociated receptors CD30 (22),  and 4-1BB (23). 
TNFRs are broadly distributed in both normal and neo- 
plastic cells and bind two related TNF molecules, TNF-ot 
and TNF-~ (24). TNF-o~ is one of the principal mediators 
of inflammation, and interaction between TNF and TNFRs 
produces a range of effects depending on the nature of the 
target cell (24). In certain tumor cells, engagement of TNFR 
by TNF induces death (24-28).  However, tumor cells and 
cell lines display variable sensitivity to TNF, some cell lines 
being readily lysed by low concentrations of TNF, whereas 
others appear to be TNF resistant even at high TNF concen- 
trations. Several TNF-resistant tumor cell lines are killed by 
TNF in the presence of inhibitors of protein synthesis. The 
mechanisms responsible for sensitivity or resistance to TNF 
are largely unknown. Furthermore, the respective role of the 
two TNFR chains in triggering cell death is disputed, some 
studies suggesting that TNFRp55 is the principal mediator 
(27, 29) whereas others contend that p75 may be equally effec- 
tive (28, 30).  Because several of the commonly used target 
cells constitutively express one or both TNFRs, it has been 
difficult to assess the effect of each receptor chain indepen- 
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between the two polypeptides has not been excluded. 
The Fas antigen is a 43-kD cell surface glycoprotein that 
is constitutively expressed in a variety of normal tissues and 
tumor cell lines while being inducible in others (12, 13). Ad- 
ministration of anti-Fas mAb in vitro (12) and in vivo (31), 
triggers apoptosis of Fas-expressing cells, suggesting that Fas 
may play a critical role in the regulation of ceU death in a 
broad range of tissues. Mutations that inactivate Fas have been 
shown to be associated with the lymphoproliferative  disorder 
of Ipr/Ipr mice (32), and Fas has recently been implicated in 
cytotoxic T  lymphocyte-mediated target cell death (33). 
Although Fas and TNFKs are currently grouped together 
as the principal cell death receptors, it is unclear whether they 
trigger the death signal along the same or distinct pathways, 
whether the potency of each receptor in any given cell is com- 
parable,  and whether their function is subject  to similar or 
distinct regulatory circuits.  To study the mechanisms that 
regulate Fas and TNFR-mediated cell death, we have devel- 
oped fusion proteins composed of the extracdlular domain 
of the B cell-associated antigen CD40 and the transmem- 
brane  and  intracellular  domain  of  Fas, TNFRp55,  and 
TNFKp75.  CD40 was chosen to provide the extracellular 
domain of the fusion proteins because it is structurally related 
to TNFR and Fas but has no known cytotoxic function. On 
the contrary, stimulation of CD40 by a natural ligand, gp39, 
induces B cell activation and Ig dass switching (34-37). CD40- 
Fas and -TNFR fusion proteins were stably expressed  in a 
human melanoma cell line that is deficient in Fas and TNFRs, 
and the transfectants tested for responses  to stimulation by 
the CD40 ligand, gp39. Our results show that all three fu- 
sion proteins induce cell death upon engagement by the gp39 
ligand. However, cellular response  to the lethal signal  cas- 
cade associated with each receptor is distinct, raising the pos- 
sibility that Fas, TNFRp55, and TNFRp75 may operate via 
different pathways. Furthermore, the effidency  of lethal signal 
delivery was observed  to be dependent upon a critical level 
of cell surface receptor expression  which may constitute a 
novel regulatory mechanism of Fas and TNFR function. 
Materials and Methods 
Development 0fCD40, Fas, TNFRp55, and TNFRp75 Fusion Pro- 
teins.  A cDNA encoding Fas was amplified from a human PHA 
blast cDNA library  by PCR using synthetic oligonucleotide  primers 
based on the published sequence (12). Primers complementary to 
the 5' and 3' extremities of the coding sequence were designed to 
contain an XhoI and a PstI endonuclease restriction site respec- 
tively, to facilitate  insertion into the CDM8 vector. Fas cDNA was 
amplified by 30 cycles of PCR (94~  for 1 min; 60~  for 2 rain; 
72~  for 3 min) using Amplitaq polymerase (Perkin Elmer, Nor- 
walk, CT) and buffer conditions recommended  by the vendor. The 
amplified sequence was subjected to XhoI and PstI endonuclease 
digestion and ligated to XhoI/PstI-cut CDM8 vector. The oligo- 
nucleotide primers were: Forward: 5'CGC GGG CTC GAG ATG 
CTG GGC ATC TGG ACC CTC CTA 3'; and Reverse: 5' CGC 
GGG CTG CAG CTA GAC CAA GCT TTG GAT TTC ATT 3'. 
Development of the CD40-Fas chimera, was facilitated by the 
presence of the BamHI site in the membrane-proximal region of 
Fas (12). To exploit this site, the BamHI site in CDM8 was re- 
moved by cutting the vector with BamHI, filling in with dNTPs, 
and religating. Fas was excised  from CDM8 with XhoI/PstI and 
inserted into XhoI/PstI-cut CDM8Bam-. All subsequent con- 
structs were made in this vector. The extracelhlar domain of  CD40 
was amplified from the CD40 cDNA (21) using synthetic 5' and 
3' oligonucleotide  primers containing  XhoI and BamHI sites, respec- 
tively. The BamHI site was designed to allow an inframe ligation 
to the Fas stalk. The oligonucleotide primers were: Forward 5': 
CAC GGG CTC GAG ATG ATT CGT CTG CCT CTG CAG 
TGC; and Reverse 5': CAC GGG GGA TCC ATC CTG GGG 
ACC ACA GAC AAC ATC AGT. Amplified  CD40 sequences were 
cut with Xhol and BamHI and ligated to XhoI/BamHI-cut Fas 
expression vector. The resulting construct contained sequences en- 
coding the extracellular  domain of CD40 and the transmembrane 
and intracellular domains of Pus. 
Sequences encoding  the transmembrane  and cytoplasmic  domains 
of human TNFR p55 and p75 were PCR amplified from corre- 
sponding cDNA  clones kindly  provided by Werner  Lessaluer 
(Hoffman-LaRoche  Ltd., Basel, Switzerland)  (18). PCR conditions 
were identical  to the ones  above  and 5' and 3' oligonucleotide  primers 
were designed to contain BamHI and NotI sites, respectively.  The 
primers were: p55 Forward: 5' CGC GGG GGA TCC ACA GTG 
CTG TTG CCC CTG GTC ATT TTC 3'; p55 Reverse: 5' CGA 
GGC GGC CGC TCA TCT GAG AAG ACT GGG CGC GGG 
3'; p75 Foward: 5' CTC GCT GGA TCC GGC GAC TTC GCT 
CTT CCA GTT GGA CTG 3'; and p75 Reverse: 5' ACA GGC 
GGC CGC TTA ACT GGG CTT CAT CCC AGC ATC AGG 
3'. To create CD40-TNFR chimeras, amplified TNFR sequences 
were subjected to BamHI and NotI digestion and ligated to the 
CD40-Fas vector, cut with B mHI/NotI to remove  the transmem- 
brane and cytoplasmic sequences of Fas. 
Sequences encoding the extracellular  domain of TNFRp55 were 
PCR amplified  according to the conditions specified  above. Oligo- 
nucleotide primers were designed to contain XhoI (5') and BamHI 
(3') restriction sites to allow inframe ligation with Fas transmem- 
brahe and intraceUular-specific  sequences. Oligonucleotide primers 
were: Forward: 5' CGC GGG CTC GAG ATG GGC CTC TCC 
ACC GTG CCT GAC CTG 3'; and Reverse: 5' CAC GGG GGA 
TCC GTC CTC AGT CGG CTT AAC ATT CTC 3'. The CD40 
extracellular domain-specific  sequences were excised from CD40- 
Fas with XhoI and BamFII  and replaced  by ligation  of  corresponding 
XhoI/BamHI-cut PCR-amplified TNFRp55  sequences, creating 
a TNFRp55-Fas chimera. 
CD44 extracellular  domain sequences were amplified  using the 
following oligonudeotide primers: Forward: 5' CAC GGG CTC 
GAG ATG GAC AAG TTT TTG TTG CAC GCA 3'; and Re- 
verse: 5' CAC GGG AGA TCT TTC TGG AAT TTG GGG TGT 
CCT TAT 3'. Amplified  CD44 extracellular  domain sequences were 
digested with XhoI and BglII and ligated to XhoI/BamHI-cut 
CD40-Fas vector, from which CD40-specific sequences had been 
excised. 
Development of Stable Transfectants.  The human melanoma cell 
line MC has been described  previously  (38). MC cells were detached 
from tissue culture plates with PBS containing 0.5 mM EDTA and 
resuspended in RPMI (Irvine Scientific,  Santa Ana, CA) at a con- 
centration of 107 ceUs/ml. CD40,  CD40-Fas, CD40-TNFRp55, 
CD40-TNFRp75,  and TNFRp55-Fas expression plasmids were 
added to 0.4 ml of cell suspension each along with the pSV2Neo 
selection vector at a ratio of 15:1/~g. Plasmids were introduced 
into the cells by electroporation, using a Gene Pulser (Bio-Rad 
Laboratories, Richmond, CA), at 625 V/cm, 960 gF. Cells were 
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(FBS)  1 (Irvine ,Scientific),  and 48 h later, the medium was replaced 
by fresh DMEM/10% FBS supplemented with 1 mg/ml G418 
(GIBCO BRL, Gaithersburg,  MD). Resistant clones  were detached 
and  tested  for  CD40  and  TNFR  expression by indirect  im- 
munofluorescence. 
Production of Sohble Recombinant CD40 Ligand.  The develop- 
ment of  a CD8-gp39 soluble fusion protein has been described  pre- 
viously (35). The CDS-gp39 expression plasmid kindly provided 
by Sandro Aruffo (Bristol Myers-Squibb, Seattle, WA) was trans- 
fected into COS cells  using DEAE-dextran/chloroquine. 12 h after 
transf~ction, the culture medium was removed  and replaced  by fresh 
serum-free DMEM. Cells were maintained in serum-free medium 
for 6-8 d, whereupon the medium was harvested. The concentra- 
tion of CD8-gp39 was estimated at 0.5-1/~g/ml on Coomassie- 
stained SDS gels. 
mAbs and Immunofluorescenc~  Parental  MC cells and transfec- 
tants were detached from culture plates with EDTA and incubated 
with 1-5/~g/ml anti-CD40 mAb $2C6 (39), anti-Fas mAb (Up- 
state Biotechnology, Inc., Lake Placid, NY), anti-TNFRp55 mAb 
htr-9 (18) or anti-TNFRp75 mAb utr-1 (18) for 45 min at 4~ 
in PBS, washed, and incubated with fluorescein-conjugated  affinity- 
purified goat anti-mouse antibody (Cappel, Malveru, PA) for 30 
min. at 4~  Cells were washed, resuspended  in PBS, and analyzed 
by flow cytometry on a FACS  |  (Becton Dickinson & Co., Moun- 
tain View, CA). To determine gp39-CD40  interaction, transfec- 
tants were incubated with CD8-gp39 supernatants for 45 rain at 
4~  washed, incubated  with fluorescein-conjugated  anti-CD8 mAb 
(Becton Dickinson & Co.), for 30 min, washed, and observed under 
an epifluorescence  microscope. 
Cytotoxicit? Assays.  To determine the cytolytic effect of CD8- 
gp39 on MC transfectants,  MC-C, MC40, MC40-Fas, MC40-p55, 
and MC40p75 were seeded  in 96-well microtiter plates (Falcon  Lab- 
ware, Oxnard,  CA) at 2  x  104 cells/well and cultured for 24 h 
in DMEM/10% FBS. Medium was then aspirated  and replaced  with 
CD8-gp39  COS  cell supernatant  or  superuatant  from  mock- 
transfected cells. Cells were incubated with COS cell supernatants 
for various times, after which the supernatants were aspirated and 
cells incubated with 0.75% crystal violet (Sigma Chemical Co., 
St. Louis, MO) in a 50% ethanol, 0.25% NaC1, and 1.75% form- 
aldehyde solution. Cells were then washed with water, air-dried, 
and dye eluted with PBS/1% SDS. Cell viability was reflected by 
dye absorbance determined by optical density measurement at 595 
nm on an automated ELISA reader. 
Results 
Development  of  C D40-Fas, - TNFR  p 55, and- TNFR  p 75 Fu- 
sion Proteins.  A cDNA insert containing the coding sequence 
of Fas (12) was amplified by PCR from a human PHA blast 
cDNA library and inserted into the CDM8 expression vector. 
Sequences encoding the secretory signal peptide and extracd- 
hlar domain of human CD40 (21) were amplified by PCR 
using synthetic oligonucleotide primers designed to contain 
endonudease restriction sites that facilitate inframe ligation 
to the Fas expression vector. The nudeotide sequence encoding 
the membrane proximal region of the extraceUular domain 
1  Abbreviations used in this paper: FBS, fetal bovine serum; MFI, mean 
fluorescence intensity. 
of human Fas contains a BamHI restriction site (12) that can 
be conveniently exploited for domain substitution. The CD40- 
Fas construct served as a cassette for subsequent switching 
of sequences encoding the transmembrane and intracellular 
regions. PCR-amplified transmembraue and intraceUular se- 
quences  of p55 and p75 TNFRs could thus be readily sub- 
stituted for their FAS counterparts. The chimeric constructs 
are iUustrated  in Fig.  1. 
Expression of CD40 and CD40-Fas,  CIMO-TNFRp55, and 
CD40-TNFRp75  Fusion  Proteins in  a  Human  Melanoma. 
Wild-type CD40 cDNA and each of the chimeric constructs 
were introduced into COS cells by the DEAE-Dextran method 
and the cells tested for expression,  48 h later, of cell surface 
CD40 by indirect immunofluorescence, using the anti-CD40 
mAb $2C6 (39). Cells expressing all of the constructs showed 
appropriate reactivity with anti-CD40 mAb (data not shown). 
The human melanoma MC (38) was chosen for establishing 
stable transfectants because it shows no reactivity with anti- 
Fas, anti-TNFR, or anti-CD40 mAb (Fig. 2), and is insensi- 
tive to anti-Fas mAb and TNF-oe (data not shown), cDNA 
cloues encoding wild-type CD40 and CD40 fusion proteins 
were cotransfected with the pSV2neo selection  plasmid, at 
a ratio of 15:1, into MC cells by electroporation and the cells 
selected for neomycin resistance.  Single neomycin-resistant 
clones  were  picked  and  tested  for  reactivity  with  anti- 
CD40mAb. Several independent clones of each transfectant, 
expressing variable  levels of the corresponding fusion pro- 
tein (Fig.  3) were obtained, and selected for further study. 
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Figure  1.  Development  of TNFR family  fusion  proteins. Extracellular 
and transmembrane/intracdhlar  components of each of the fusion  pro- 
teins used are indicated. Amino  acid sequences corresponding  to the ex- 
tracdlular domain (plain typeface)  and the transmembrane/intracdlular 
domain (italics) at each  junction are shown. The vertical line represents 
the call membrane. 
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Figure  2.  The parental MC melanoma cell line is deficient in CD40, 
Fas, and TNFR expression. The parental MC cell line was tested for the 
expression of Fas (.4), CD40 (B), TNFRp55 (C), and TNFRp75 (D) by 
flow cytometry. Cells were stained with anti-Fas mAb, anti-CD40 mAb 
$2C6, anti-TNFrp55 mAb htr-9, and anti-TNFR.p75 mAb utr-1, followed 
by a fluorescein-conjugated,  affinity-purified  goat anti-mouse antibody, 
and analyzed by FACScan  |  The relative cell number is plotted against 
log fluorescence intensity. 
Transfectants expressing wild-type CD40 (MC40) and selec- 
tion vector only (MC-C) were used as controls. The panel 
of transfectants used throughout the study are listed in Table 1. 
Engagement  of CD40 Fusion Proteins by CDS-gp39 Induces 
Lethal Signals in MC Transfectants.  To assess the functional 
properties of the fusion proteins,  we used a  soluble recom- 
binant  form  of a  cell surface CD40  ligand (35).  CD40  has 
recently been shown to interact with gp39, a type II integral 
membrane  protein expressed on  activated T  cells (34,  35). 
Table  1.  Fusion Protein Expression Level in MC Transformants 
Fusion protein 
MC  transformants  expression level 
MC40-Fas  19  + 
13  +  + 
5bis  +  + 
5  ++ 
10  +  + 
6  +++ 
14  +++ 
4  +++ 
MC40-p55  15  +  + 
31  +  + 
2  + 
MC40-p75  15  +  + 
17bis  +  + 
20  + 
MCC 
MC40  9  +  +  + 
MCTNFp55-Fas  3  +  + 
5  ++ 
12  +  + 
13  +  + 
15  + 
MFI is graded as follows: ( + ) MFI <  20, low expression;  ( + + ) 20 > 
MFI <  150,  intermediate expression;  (+ +  +) MFI >  150,  high ex- 
pression. 
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Figure 3.  ExpressionofCD40-FasfusionproteininMCtransfectants. 
The parental cell line (MC) and three representative transfectants  (5, 5his, 
and 14) expressing CD40-FAS fusion protein were incubated with anti- 
CD40 $2C6  mAb followed by fluorescein-conjugated  goat anti-mouse 
antibody and analyzed by FACScan  |  Histograms show relative cell number 
versus log fluorescence intensity. 
A recombinant soluble form of gp39, fused to the extracel- 
lular domain of CD8 has been developed and shown to re- 
tain its CD40-binding and stimulatory properties (35). The 
CDS-gp39 fusion protein was observed to bind all transfec- 
tants expressing wild-type CD40 and CD40 fusion proteins 
(data not shown), and thus provided a suitable means to de- 
termine whether ligand-dependent engagement of CD40 
might trigger activity of the intracellular  Fas and TNFR 
domains. 
Representative MC40-Fas,  MC40-p55,  and  MC40-p75 
clones were incubated in microtiter wells with serum-free 
COS cell supernatants containing CDS-gp39, and observed 
by light microscopy for signs of cell death at multiple in- 
tervals over a 48-h period. MC40-Fas cells showed marked 
morphologic changes within 2 h of incubation, character- 
ized by cell rounding, formation of surface blebs and chro- 
matin condensation, corresponding to those associated with 
apoptosis (Fig. 4 and data not shown). MC40-p55 and MC40- 
p75 cells displayed similar morphologic changes but at a later 
560  Fas and TNF Receptor-mediated Cell Death Figure 4.  Transfectant  cell  death  induced  by CDS-gp39. One representative  clone  of  each  of  the MC40-Fas (A-C), MC40-p55 (D-F), and MC40-p75 
(G-/) transfectants  was incubated  with serum-free  CDS-gp39 COS cell supernatants. Microphotographs  were taken at time 0 (,4,/~  and G), 3 (~ 
E, and/4) and 30 h (C, F, and/), on a Nikon Diaphot.  x 40. 
time point, typically between 24 and 48 h after the start of 
incubation with CD8-gp39 supernatant. Apoptosis of MC40- 
Fas cells could be observed after pulsing the cells with CD8- 
gp39 for 15 min and replacing the supernatants with fresh, 
serum-free media, suggesting a high degree of sensitivity to 
Fas-associated  death signals.  MC40 transfectants, expressing 
wild-type CD40, were unaffected  by CDS-gp39 superuatants 
as were MC-C and parental cells (data not shown), indicating 
that cell death was not due to the potential toxicity of the 
supernatants themselves. It is interesting to note that none 
of the transfectants were susceptible to anti-CD40 $2C6 mAb, 
which recognizes a CD40 epitope distinct from that bound 
by gp39 (Clement, M.-V., and I. Stamenkovic, unpublished 
results), even at high mAb concentrations (data not shown), 
nor did cross-linking of $2C6 by secondary antibodies have 
any effect. 
The Efficiency of  Fas-raediated Cytotoxicity  Depends on a Crit- 
ical Level of  Receptor Expression.  To address the possible corre- 
lation between the level of fusion protein expression and the 
rapidity of cell death after triggering of CD40-Fas, eight in- 
dependent MC40-Fas transfectant clones were tested for their 
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response to CD8-gp39.  Clones were designated as low, in- 
termediate,  and  high  expressors  according to  their  mean 
fluorescence intensity (MFI) as determined by flow cytom- 
etry using the anti-CD40 $2C6 mAb: clones with MFI <20 
were designated as low,  20-150 as intermediate, and ~150 
as high expressors (Table 1). Cell death was assessed at sev- 
eral time points by measuring the incorporation of crystal 
violet as an indicator of  cell viability. Four of  the clones, MC40- 
Fas 5, 5bis,  10, and 13 were killed rapidly, with a half max- 
imal response of <2 h. Maximal cell death occurred at 6 h 
after stimulation, with only 20-30% of  cells remaining viable 
(Fig. 5). Viability of these calls at 24 h remained at 15-25% 
(data not shown). The remaining four dones, MC40-Fas 4, 
6,  14, and 19, displayed partial or near complete resistance 
to CD8-gp39 stimulation, with 60-95% viability at 6 h. At 
24 h, however, viability of these clones fell to 40-70% (data 
not  shown),  consistent with reduced effectiveness  of Fas- 
mediated cytotoxidty. Remarkably, three of the four resis- 
tant clones, MC40-Fas 4, 6, and 14 were high expressors of 
CD40-Fas (Fig. 5, and Table 1), whereas the fourth, MC40- 
Fas 19, expressed the fusion protein weakly. The four most 100 4 
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Figure 7.  Time course of gp39-mediated  killing of MC40-p55  and 
MC40-p75 transfr  MC40-p55 (.4) and MC40-p75 (B) transfectants, 
and MC cells transfected with pSV2neo alone (Neo) were incubated with 
CDS-gp39 COS cell supernatants at 37~  for 3 d and stained with crystal 
violet at various time points to determine the percent viability. Data shown 
are representative of four independent experiments. 
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Figure 6.  Sensitivity of MC40-Fas transfectants to Gp39 cytotoxicity. 
Three MC40-Fas (CD40-FAS 5his, CD40-FAS 19, and CD40-FAS 14) trans- 
fectants representing different fusion protein expression  levels  were incubated 
with serially diluted serum-free CD8-gp39 COS cell supernatants at 37~ 
for 24 h and stained with crystal violet. The percentage of viable cells 
was determined as described in Materials and Methods. The data shown 
are the means of four independent experiments. SD <5%. 
sensitive clones expressed an intermediate level of the CD40- 
Fas fusion protein (Fig.  5,  and Table 1). The difference in 
susceptibility to cell death among the clones could be more 
clearly demonstrated after a 24-h incubation with serial dilu- 
tions of CDS-gp39 (Fig. 6). The lowest expressor, MC40- 
Fas.19, was resistant to the lethal effect of CD8-gp39  at a 
1:4 dilution  of the supernatant. The intermediate expressor 
MC40-Fas.5bis, on the other hand, displayed high suscepti- 
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responded more slowly to CD8-gp39 than MC40-Fas cells, 
85-95%  of the cells displaying viability at 24 h. Maximal 
cell death  was observed  at  72 h, when the most  sensitive 
MC40-p55 and MC40p-75 clones displayed 30 and 50% via- 
bility, respectively (Fig. 7). Within each group, low expressors 
were the most sensitive to CD8-gp39 whereas intermediate 
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Figure 8.  Effect  of cycloheximide  on gp39-dependent cell death of 
MC40-p55 and MC40-p75 transfectants.  One representative  MC40-p55 
clone (CD40p55  2) (.4) and one representative MC40-p75 clone (CD40p75 
17bis) (B) were incubated for 3 d with COS cell supernatants  containing 
CD8-gp39 in the presence or absence of cyclohexamide (5/~g/ml) and 
the percentage of viable cells determined by crystal violet staining.  MC 
cells transfected with pSV2neo alone were not affected by cycloheximide 
treatment. The data shown are the mean of three independent experiments. 
SD were within 5%. 
bility to cell death even at a 1:8 dilution of the CD8-gp39 
supernatant (Fig. 6). High expressors, exemplified by MC40- 
Fas 14, were consistently less sensitive than clones displaying 
intermediate  level expression. 
MC40.p55 and MC40-p75 TNFRs Show Distinct Responses 
to CD8-gp39.  Three independent MC40-p55  and MC40- 
p75 clones were obtained (Table 1). Both sets of transfectants 
563  Clement and Stamenkovic 
B 
100 
0  1/2 
CD8-gp39 
1/4  1/8  1/16 
supernatant  dilution 
[]  CD40-FAS  t4 
6o 
~=~ 
'==  6o 
.Q 
40 
0 
20 
0  1/2  1/4  1/8  1/16 
CD8-gp39  supernatant  dilution 
Figure 9.  Effect of cyclohexirnide  on gp39-dependent cell death of 
MC40-Fas transfectants. Two representative MC40-Fas clones (CD40-FAS 
5bis l  A] and CD40.FAS14 [B] ) were incubated for 6 h in serial dilutions 
of CD8-gp39 COS cell supernatants in the presence or absence of cyclo- 
heximide (5/~g/ml) at 37~  and viability determined by staining with 
crystal violet. MC cells transfected with pSV2neo alone were not affected 
by cycloheximide. Data shown are representative of three independent ex- 
periments. expressors (according to the designation in Table 1) responded 
the least (Fig.  7,  and Table 1). 
Inhibition of  Protein Synthesis Enhances Ligand-mediated Cy- 
totoxicity in MC40-Fas and MC40-p55 but not in MC40-p75 
Transfectants.  A clear distinction between MC40-p55 and 
MC40-p75 cell response to gp39 stimulation was observed 
in the presence of cydoheximide (Fig. 8). Whereas suscepti- 
bility of MC40-p55 cells to gp39 was markedly increased by 
cydoheximide, resulting in maximal cell death within 24 h, 
MC40-p75 sensitivity was not altered  (Fig.  8).  Similar  to 
MC40-p55 cells, susceptibility of MC40-Fas transfectants to 
CD8-gp39 was enhanced by cydoheximide (Fig. 9). The rate 
at which the most sensitive MC40-Fas clones were killed after 
triggering by CDS-gp39 (maximal cell death was observed 
at 6 h) was not significantly altered by addition of cydohexi- 
mide (data not shown), but the fraction of ceUs susceptible 
to Fas-induced cytotoxicity was increased (Fig. 9). The poten- 
tiating effect of cydoheximide could be best demonstrated 
when MC40-Fas clones of different sensitivity were incubated 
with serial dilutions of CD8-gp39 supernatants in the pres- 
ence or absence of the drug (Fig.  9).  Cydoheximide sig- 
nificantly reduced the  threshold of sensitivity to ligand- 
mediated Fas cytotoxicity in all transfectants  tested (Fig. 9, 
and data not shown). Furthermore, maximal cell death, even 
of partially resistant dones, was observed within 6 h in the 
presence of cydoheximide (data not shown). 
TNFR-Fas and CD40-Fas Fusion Proteins Transduce  Similar 
Cytotoxic Signals Whereas CD44-Fas Fails to  Induce Cell 
Death.  To determine whether intracdlular and transmem- 
brane Fas segments retain cytotoxic signaling properties when 
fused  to  the  extracellular  domain  of  other  receptors,  a 
TNFRp55-Fas chimera was designed and expressed in MC 
cells. Five stable transfectants were obtained. One of the trans- 
fectants expressed TNFRp55-Fas in the low range (MFI <20) 
and was resistant to TNF (Fig. 10), reminiscent of low CD40- 
Fas expressor resistance to CD40 ligand (Fig. 5). Each of the 
other four transfectants displayed inhomogeneous  expression 
of the fusion protein covering low and intermediate levels 
with an MFI in the intermediate range of 42-61. All four 
isolates were sensitive to TNF at a concentration of 6 ng/ml, 
with maximal cell death occurring within 6 h (Fig. 10), similar 
to corresponding CD40-Fas transfectants  exposed to CD8- 
gp39. Augmenting TNF concentration to 25 ng/ml failed 
to increase its cytotoxic effect (Fig.  10), but addition of cy- 
cloheximide augmented transfectant sensitivity to TNF, ren- 
dering as little as 0.6 ng/ml lethal (data not shown). How- 
ever, only about 50% of cells from each of the transfectants 
were killed by TNF (Fig.  10). This observation most likely 
reflects the broad range of TNFtLp55-Fas fusion protein ex- 
pression in each isolate. Roughly 50% of cells expressed a 
low level of TNFRp55-Fas which, in the case of CD40-Fas 
transfectants  and one TNFRp55-Fas-expressing done, was 
associated with resistance to ligand-induced, Fas-mediated cy- 
totoxicity (Figs. 5 and 10). To determine the phenotype of 
surviving cells after exposure to TNF, a representative  low 
to intermediate level  TNFRp55-Fas expressor was treated with 
100 ng/ml TNF for 6 h, and the supernatant removed and 
replaced with fresh culture medium. After 24 h of culture, 
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Figure 10.  Cytotoxic effect of TNF-oL on MC TNFp55-Fas transfor- 
mants. MC TNFp55-Fas clones were incubated for 6 h with various con- 
centrations of TNF-o~ at 37~  and viability determined by staining with 
crystal violet. MC cells transfected with the pSV2neo alone (MC C) were 
not affected by the TNF-o~ treatment. Data shown are representative of 
three independent experiments. 
surviving cells were incubated with anti-TNFRp55 mAb htr-9 
and subjected to FACS  |  analysis. The majority of the cells 
expressed low TNFRp55-Fas levels whereas most of the in- 
termediate expressor population was depleted (Fig. 11). Thus, 
intermediate and low TNFRp55-Fas and CD40-Fas expressors 
displayed similar susceptibility to ligand-induced cytotoxicity. 
It is interesting to note that cells expressing a CD44-Fas 
fusion protein were resistant to anti-CD44 mAb triggering, 
as  well  as  to  stimulation by  soluble  and  surface-bound 
hyaluronate,  the principal CD44 ligand (40,  41) (data  not 
shown). Resistance was not due to high or low fusion pro- 
tein expression,  as transfectants expressing a broad range of 
CD44-Fas  levels were obtained and tested. 
! 
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Figure 11.  Expression of TNFR-p55-Fas fusion protein in a represen- 
tative transfectant (.4) before and (B) after a 6-h incubation with TNF 
at 100 ng/ml. Expression  was tested by FACS  ~ analysis  using anti-TNFKp55 
mAb htr-9, 24 h after removal of TNF from the culture supernatant. The 
cell population expressing intermediate levels  of fusion protein (as defined 
in this study) is marked by cursors at FI 20 and 200. Reactivity of an 
unrelated,  isotype-matched antibody is represented by the dotted line. 
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In the present  work, we have developed an approach to 
fadlitate the study and comparison of Fas and TNFR-mediated 
cell death. Our strategy  has relied on two critical factors: 
the choice of a human tumor cell line that does not respond 
to TNF-ot or anti-Fas mAb and that is deficient in Fas and 
TNFR expression, and the creation and expression of fusion 
proteins  that bear a common extracellular domain that can 
be triggered by the same natural ligand. This combination 
has revealed that the three receptors have both common and 
distinct functional characteristics. 
Engagement of receptors by specific  ligands, or cross-linking 
by specific  mAb, usually causes receptor dimerization or oligo- 
merization which promotes recruitment of mediators  that 
trigger a signaling cascade. It has been proposed that the ex- 
tracellular domain of cell surface receptors may primarily serve 
to facilitate ligand-induced clustering of the cytoplasmic do- 
main which is responsible for signal release (42). Our results 
show that replacement of the extracellular domain of Fas and 
TNFRs by that of different molecules of the same receptor 
family does not abrogate transduction of lethal signals upon 
stimulation with corresponding ligands, indicating that ex- 
pression of the extracellular domain of Fas and TNFRs is 
not required for triggering cell death. However, appropriate 
ligand-mediated clustering appears to be critical, as anti-CD40 
mAb $2C6, which is costimulatory with inducers of B cell 
activation (39), but recognizes an epitope distinct from that 
bound by gp39 (Clement, M.-V., and I. Stamenkovic, un- 
published results), had no effect on the MC40-Fas and -TNFK 
transfectants even after extensive cross-linking by secondary 
antibody. Similarly, replacement of the extracellular domain 
of Pas by that of the hyaluronate receptor CD44 generated 
fusion proteins that could not induce cytotoxicity in MC cells 
after antibody or ligand-mediated cross-linking. The CD40 
ligand, gp39, on the other hand, induced cytotoxic signals 
in all three transfectants,  as did TNF-oe in MCTNFKp55- 
Fas cells. The TNF-ot molecule has been shown to possess 
three receptor binding sites, which induce the formation of 
TNFK trimers upon engagement (43), and it has been sug- 
gested  that  gp39  may have a similar effect on the CD40 
receptor  (36).  These observations  support the notion that 
the CD40, Fas, and TNF receptors may share similar oligo- 
merization requirements for appropriate ligand-mediated sig- 
naling. 
Stable transfectants expressing CD40-Fas, TNFKp55-Fas, 
and CD40-TNFK fusion proteins have helped demonstrate 
that the transmemhrane/intracellular  domains of Fas, TNFK 
p55,  and TNFKp75 can each mediate cell death indepen- 
dently. However, several distinctive functional properties have 
emerged. Whereas Fas-dependent signals induced cell death 
within hours of stimulus, in the most sensitive clones, detec- 
tion of TNFR-dependent cytotoxicity required 2-3 d of ex- 
posure to ligand. The two CD40-TNFR fusion proteins dis- 
played  comparable  cytotoxic  signaling  in  MC  cells, but 
TNFKp55-dependent cytotoxicity was enhanced by inhibi- 
tots of protein synthesis, whereas TNFl~p75-related signals 
were unaffected. The kinetics of Fas-dependent cytotoxicity 
was not significantly altered by cydoheximide in the most 
sensitive clones, suggesting that the observed death rate might 
reflect maximal efficiency of Fas-dependent  cytotoxicity in 
these  cells. However,  the threshold of sensitivity  to  Fas- 
mediated cell death in partially resistant clones was reduced 
by addition of cydoheximide. Thus, in MC melanoma cells, 
Fas and TNFKp55-associated cytotoxic signaling may be sub- 
ject to the regulatory action of inhibitory intraceUular pro- 
teins whereas the cytolytic function of TNFRp75  appears 
to be independent of similar control mechanisms. 
Finally, our model suggests  that the efficacy of Fas and 
TNFR cytotoxic signals may be dependent on a critical level 
of receptor surface expression. Intermediate levels of CD40- 
Fas and low levels of CD40-TNFK expression were associated 
with the most rapid and extensive killing in response to the 
CD40 ligand, whereas cells displaying high levels of fusion 
protein expression were partially resistant, and were rendered 
sensitive only in the presence of cycloheximide. Sensitivity 
of tumor cells to lethal signals from endogenous TNFRs and 
Fas is known to be highly variable (24, 44, 45), consistent 
with the possibility that the activity of TNFK and Fas may 
be subject to cell type-specific  regulation. The results presented 
here are consistent with the notion that the stoichiometry 
of the interaction between receptors, inhibitors  of receptor 
function and second messengers that constitute the signaling 
cascade, may provide such a regulatory mechanism. Cell sur- 
face receptor signal transduction requires ligand-mediated 
receptor clustering that is thought to be necessary for any 
given signaling threshold to be reached. Optimal signal trans- 
duction presumably  requires interaction between a critical 
fraction of receptors forming the ligand-mediated duster and 
specific second messenger molecules. Limitation of interac- 
tions between second messenger molecules and receptors by 
any number of possible mechanisms, including low steady 
state second messenger abundance, high turnover,  or com- 
petitive  binding by  other molecules,  would predict  that 
receptor overexpression may result in receptor saturation  of 
the messenger pool, and the presence of excess "free" receptors. 
Since ligand engagement of receptors is random, the fraction 
of receptors, within ligand-induced aggregates, which com- 
municate with appropriate messengers would be reduced, and 
signaling efficiency potentially lowered. A simple explana- 
tion for ineffective cytotoxic  signaling by transfectants  ex- 
pressing high levels of Fas and TNFK fusion proteins, might 
therefore be a receptor/messenger  imbalance. Removal of in- 
hibitor molecules by blockers of protein synthesis, on the other 
hand, may reduce the signaling threshold, and partially re- 
store triggering of TNFKp55 and Fas-associated death signals 
despite suboptimal receptor-messenger interaction.  Because 
receptor, second messenger, and receptor inhibitor stoichiom- 
etry is likely to vary among cell types, it is conceivable that 
efficient cytotoxicity might require high receptor expression 
in  some  cells and low  expression  in  others.  The  model 
presented here may provide a means to help elucidate some 
of the mechanisms  that regulate TNFR/Fas-mediated cell 
death. 
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